Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 130

1.

Long-term safety and efficacy of two different antimuscarinics, imidafenacin and solifenacin, for treatment of overactive bladder: a prospective randomized controlled study.

Yokoyama T, Koide T, Hara R, Fukumoto K, Miyaji Y, Nagai A.

Urol Int. 2013;90(2):161-7. doi: 10.1159/000345055. Epub 2012 Nov 27.

PMID:
23207959
2.

Randomized, double-blind, placebo- and propiverine-controlled trial of the once-daily antimuscarinic agent solifenacin in Japanese patients with overactive bladder.

Yamaguchi O, Marui E, Kakizaki H, Itoh N, Yokota T, Okada H, Ishizuka O, Ozono S, Gotoh M, Sugiyama T, Seki N, Yoshida M; Japanese Solifenacin Study Group.

BJU Int. 2007 Sep;100(3):579-87.

3.

Tolerability of 5 mg solifenacin once daily versus 5 mg oxybutynin immediate release 3 times daily: results of the VECTOR trial.

Herschorn S, Stothers L, Carlson K, Egerdie B, Gajewski JB, Pommerville P, Schulz J, Radomski S, Drutz H, Barkin J, Paradiso-Hardy F.

J Urol. 2010 May;183(5):1892-8. doi: 10.1016/j.juro.2010.01.012. Epub 2010 Mar 29.

PMID:
20303119
4.

Severity of overactive bladder symptoms and response to dose escalation in a randomized, double-blind trial of solifenacin (SUNRISE).

Cardozo L, Amarenco G, Pushkar D, Mikulas J, Drogendijk T, Wright M, Compion G; SUNRISE Study Group.

BJU Int. 2013 May;111(5):804-10. doi: 10.1111/j.1464-410X.2012.11654.x. Epub 2013 Jan 7.

5.

Efficacy and tolerability of solifenacin in elderly subjects with overactive bladder syndrome: a pooled analysis.

Wagg A, Wyndaele JJ, Sieber P.

Am J Geriatr Pharmacother. 2006 Mar;4(1):14-24.

PMID:
16730617
6.

Solifenacin and tolterodine are equally effective in the treatment of overactive bladder symptoms.

Ho CH, Chang TC, Lin HH, Liu SP, Huang KH, Yu HJ.

J Formos Med Assoc. 2010 Oct;109(10):702-8. doi: 10.1016/S0929-6646(10)60114-3.

7.

Efficacy of solifenacin in patients previously treated with tolterodine extended release 4 mg: results of a 12-week, multicenter, open-label, flexible-dose study.

Chancellor MB, Zinner N, Whitmore K, Kobashi K, Snyder JA, Siami P, Karram M, Laramée C, Capo' JP Jr, Seifeldin R, Forero-Schwanhaeuser S, Nandy I.

Clin Ther. 2008 Oct;30(10):1766-81. doi: 10.1016/j.clinthera.2008.10.011.

PMID:
19014833
8.

Solifenacin for overactive bladder: patient-reported outcomes from a large placebo-controlled trial.

Toglia MR, Serels SR, Laramée C, Karram MM, Nandy IM, Andoh M, Seifeldin R, Forero-Schwanhaeuser S.

Postgrad Med. 2009 Sep;121(5):151-8. doi: 10.3810/pgm.2009.09.2062.

PMID:
19820284
9.

Which anticholinergic drug for overactive bladder symptoms in adults.

Madhuvrata P, Cody JD, Ellis G, Herbison GP, Hay-Smith EJ.

Cochrane Database Syst Rev. 2012 Jan 18;1:CD005429. doi: 10.1002/14651858.CD005429.pub2. Review.

PMID:
22258963
10.

Solifenacin in women with de novo overactive bladder after tension-free obturator vaginal tape--is it effective?

Serati M, Braga A, Sorice P, Siesto G, Salvatore S, Ghezzi F.

J Urol. 2014 May;191(5):1322-6. doi: 10.1016/j.juro.2013.10.068. Epub 2013 Oct 19.

PMID:
24148761
11.

Safety and tolerability of solifenacin add-on therapy to α-blocker treated men with residual urgency and frequency.

Kaplan SA, McCammon K, Fincher R, Fakhoury A, He W.

J Urol. 2013 Jan;189(1 Suppl):S129-34. doi: 10.1016/j.juro.2012.11.030.

PMID:
23234618
12.

Safety and tolerability of solifenacin add-on therapy to alpha-blocker treated men with residual urgency and frequency.

Kaplan SA, McCammon K, Fincher R, Fakhoury A, He W.

J Urol. 2009 Dec;182(6):2825-30. doi: 10.1016/j.juro.2009.08.023. Epub 2009 Oct 17.

PMID:
19837435
13.
14.

Solifenacin in the treatment of urgency and other symptoms of overactive bladder: results from a randomized, double-blind, placebo-controlled, rising-dose trial.

Cardozo L, Hessdörfer E, Milani R, Arañó P, Dewilde L, Slack M, Drogendijk T, Wright M, Bolodeoku J; SUNRISE Study Group.

BJU Int. 2008 Nov;102(9):1120-7. doi: 10.1111/j.1464-410X.2008.07939.x. Epub 2008 Oct 6.

15.

Solifenacin for overactive bladder with incontinence: symptom bother and health-related quality of life outcomes.

Garely AD, Lucente V, Vapnek J, Smith N.

Ann Pharmacother. 2007 Mar;41(3):391-8. Epub 2007 Mar 6.

PMID:
17341526
16.

Solifenacin treatment in men with overactive bladder: effects on symptoms and patient-reported outcomes.

Kaplan SA, Goldfischer ER, Steers WD, Gittelman M, Andoh M, Forero-Schwanhaeuser S.

Aging Male. 2010 Jun;13(2):100-7. doi: 10.3109/13685530903440408.

PMID:
20001469
17.

Long-term open-label solifenacin treatment associated with persistence with therapy in patients with overactive bladder syndrome.

Haab F, Cardozo L, Chapple C, Ridder AM; Solifenacin Study Group.

Eur Urol. 2005 Mar;47(3):376-84. Epub 2005 Jan 5.

PMID:
15716204
18.
19.

Long-term safety, tolerability, and efficacy of the novel anti-muscarinic agent imidafenacin in Japanese patients with overactive bladder.

Homma Y, Yamaguchi O.

Int J Urol. 2008 Oct;15(11):986-91. doi: 10.1111/j.1442-2042.2008.02152.x. Epub 2008 Aug 28.

20.

Solifenacin provides effective antimuscarinic therapy for the complete management of overactive bladder.

Chapple CR.

Expert Opin Pharmacother. 2006 Dec;7(17):2421-34. Review.

PMID:
17109616
Items per page

Supplemental Content

Write to the Help Desk